Drug Search Results
More Filters [+]

GSK-2590066A

Alternative Names: GSK-2590066A, GSK2590066A, GSK 2590066A, GSK-2590066, GSK2590066, GSK 2590066
Latest Update: 2017-05-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2590066A

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Influenza, Human

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01236040

P1

Completed

Influenza, Human

2011-09-06

Recent News Events

Date

Type

Title